“迷失在海上”一词的意思是迷惑或困惑。延伸来说，《Lost at SCLC》提到了目前关于如何规避化疗耐药性的困惑，尤其是铂耐药性，这种耐药性严重困扰了广泛期小细胞肺癌 (ES-SCLC) 的治疗，以至于 2012 年美国国家癌症研究所 (NCI)将其命名为“顽固性癌症”。十多年后，尽管免疫检查点抑制剂获得批准，Lurbinectedin 有条件获得批准，但 ES-SCLC，尤其是铂类耐药 ES-SCLC 的预后几乎没有改善。本综述简要总结了目前 ES-SCLC 的治疗方案，重点是五种临床阶段的疗法，这些疗法有可能成功逆转铂类耐药性，这可能是获得更好临床结果的最大障碍。© 2024。作者（ s）。

The expression "lost at sea" means to be confused or perplexed. By extension, lost at SCLC references the current confusion about how to circumvent the chemoresistance, particularly platinum resistance, which so plagues the treatment of extensive-stage small cell lung cancer (ES-SCLC) that in 2012 the US National Cancer Institute (NCI) designated it a "recalcitrant cancer." Over a decade later, despite the approval of immune checkpoint inhibitors and the conditional approval of lurbinectedin, the prognosis for ES-SCLC, and especially platinum-resistant ES-SCLC, has scarcely improved. The focus of this review, which briefly summarizes current treatment options for ES-SCLC, is on five clinical-stage therapies with the potential to successfully reverse the platinum resistance that is perhaps the biggest obstacle to better clinical outcomes.© 2024. The Author(s).